Spectral Diagnostics (SDI.TO) Announces Enrollment Milestone for Its EUPHRATES Trial
12/5/2012 10:00:27 AM
TORONTO, Dec. 5, 2012 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with septic shock, today announced that 76 patients have been randomized into its EUPHRATES trial and have been followed for 28 day mortality assessment in accordance with the trial's protocol.
A meeting of the trial's Data and Safety Monitoring Board (DSMB) has been scheduled for the end of January, 2013. The DSMB will evaluate the interim data to determine if there are any safety concerns and if they are satisfied with the study conduct. Spectral anticipates that it will disclose the details of this interim analysis by the end of February, 2013.
comments powered by